Chemical and Pharmaceutical Bulletin · 2007 · 15 citations · 11 references
PharmacyPharmacokineticsPharmacologyBioavailabilityDrug DiscoveryProdrug DesignDrug DispositionIn Vitro PharmacologyOral Prodrugs
A series of carbamates of the phenolic compound 1 were prepared and evaluated in vivo as its prodrug. Each carbamate was orally administered to rats, and plasma concentrations of the parent compound 1 were measured with the passage of time. We judged which carbamate was suitable for the prodrug of 1 from both the AUC value of 1 and absence of the carbamate in plasma. The AUC value of 1 after oral administration of 2b was approximately 40-fold higher than that for an administration of 1, and the bioconversion from 2b to 1 was excellent. As a whole, di-substituted carbamates resulted in higher plasma concentrations of 1 than did mono-substituted ones. However di-substituted carbamates were almost always detected in plasma. As a result, we found that the ethycarbamoyl derivative 2b demonstrates the best prodrug property in this series.
11
Seigo Sawada, Satoru Okajima, Ritsuo Aiyama et al. · Chemical and Pharmaceutical Bulletin · 1991 · 233 citations · Full text
Youhei Sohma, Yoshio Hayashi, Tomoko Ito et al. · Journal of Medicinal Chemistry · 2003 · 39 citations
Synthesis and Antitumor Activity of Duocarmycin Derivatives.
Satoru Nagamura, Eiji Kobayashi, K Gomi et al. · Chemical and Pharmaceutical Bulletin · 1995 · 36 citations · Full text